Endogenous / BiologyEndogenousHuman-supportedUpdated 2026-04-24

Peptide reference file

Cholecystokinin

Trending #27 in Endogenous8.4k searches/moProven

Cholecystokinin is an endogenous gut peptide involved in satiety, gallbladder contraction, and digestive signaling.

Current readout: human-supported evidence, endogenous status, endogenous approval state, human evidence appears in the current trail, registered trials are linked, and 3 linked sources in the seed trail.

PubChem CID 9833444 | 48839 PubMed results | 31 trial records | 0 DailyMed labels | 0 Drugs@FDA applications

Cholecystokinin is mostly discussed because it helps explain appetite and digestive peptide biology beyond the incretin family.

The public claim is straightforward: It helps explain appetite and digestive peptide biology beyond the incretin family. High-confidence peptide physiology reference entry.

In plain language, cholecystokinin is an endogenous gut peptide involved in satiety, gallbladder contraction, and digestive signaling.

Human-supportedEndogenous
Gut hormoneSatiety signalingDigestive control

Aliases: CCK, CCK-8

SpecimenCholecystokinin specimen
CCCCCCHHHHHHHNOOS
Formula
C49H62N10O16S3
Mass
1143.3
Evidence
Human-supported
Elements
5

Most commonly discussed in relation to Gut hormone, Satiety signaling, Digestive control.

What Cholecystokinin is

Cholecystokinin is an endogenous gut peptide involved in satiety, gallbladder contraction, and digestive signaling.

Cholecystokinin is grouped under Endogenous / Biology / Fat Loss + GLP-1s on PeptideFactCheck because it helps explain appetite and digestive peptide biology beyond the incretin family.

The useful starting point is to separate the molecule itself from the internet story around it. It helps explain appetite and digestive peptide biology beyond the incretin family.

Why people keep looking it up

It helps explain appetite and digestive peptide biology beyond the incretin family.

Cholecystokinin is an endogenous gut peptide involved in satiety, gallbladder contraction, and digestive signaling.

Cholecystokinin tends to stay in the conversation because it touches a familiar public theme: gut hormone, satiety signaling, and digestive control. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

High-confidence peptide physiology reference entry.

Human physiology is well described, though this is mostly a reference entry rather than a commercial peptide story.

Mechanistic support across digestive and satiety physiology is strong.

Why this page carries the current tier: High-confidence peptide physiology reference entry.

The current seed trail for Cholecystokinin is pulling from 2 databases sources and 1 literature source.

Safety, limits, and regulatory context

It should be treated as physiology first, not marketing copy.

CCK is tracked here as endogenous biology.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Cholecystokinin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for Cholecystokinin is CID 9833444. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
9833444
Formula
C49H62N10O16S3
Molecular weight
1143.3
InChIKey
IZTQOLKUZKXIRV-YRVFCXMDSA-N

Matched synonyms include Sincalide, 25126-32-3, CCK-8, Kinevac, Sincalida, CCK-8S, Sincalidum, Syncalide.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for Cholecystokinin returns 31 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for Cholecystokinin returns 48839 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Label and regulatory records

For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.

Brand names
Melancholy Drops Extrovert 2015
Generic names
MELANCHOLY DROPS EXTROVERT
Routes
ORAL
Application numbers
Not linked

Indications and usage. INDICATIONS For the temporary relief of sadness or fatigue, particularly in those with extroverted personality.*

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.